{"id":"pegaptanib-sodium-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Anterior chamber inflammation"},{"rate":null,"effect":"Cataracts"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL1201421","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegaptanib is a pegylated RNA aptamer that specifically targets VEGF165, the predominant isoform involved in pathological neovascularization. By blocking VEGF signaling, it reduces vascular permeability and inhibits the formation of new abnormal blood vessels in age-related macular degeneration, thereby slowing vision loss.","oneSentence":"Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:04.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT00790803","phase":"NA","title":"Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":"Uveitis, Cystoid Macular Edema","enrollment":5},{"nctId":"NCT01573572","phase":"PHASE4","title":"Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-04-22","conditions":"Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":131},{"nctId":"NCT00549055","phase":"","title":"A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":38},{"nctId":"NCT00605280","phase":"PHASE2, PHASE3","title":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Macular Edema Associated With Diabetes Mellitus","enrollment":317},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT00242580","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":111},{"nctId":"NCT00845273","phase":"","title":"Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Macular Degeneration","enrollment":3538},{"nctId":"NCT01218230","phase":"NA","title":"Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia","status":"WITHDRAWN","sponsor":"L.V. Prasad Eye Institute","startDate":"2010-12","conditions":"Myopic Choroidal Neovascular Membrane","enrollment":""},{"nctId":"NCT01281098","phase":"PHASE2","title":"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2010-03","conditions":"High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II","enrollment":22},{"nctId":"NCT00320775","phase":"PHASE1","title":"Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2005-06","conditions":"Macular Degeneration","enrollment":51},{"nctId":"NCT00820742","phase":"","title":"Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2008-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT01175070","phase":"PHASE4","title":"Intravitreal Macugen for Ischaemic Diabetic Macular Oedema","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-01","conditions":"Diabetic Macular Oedema","enrollment":30},{"nctId":"NCT00709657","phase":"NA","title":"The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor","enrollment":8},{"nctId":"NCT00406107","phase":"PHASE4","title":"Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2006-01","conditions":"Branch Retinal Vein Occlusion","enrollment":20},{"nctId":"NCT01589718","phase":"PHASE3","title":"A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy","status":"WITHDRAWN","sponsor":"Greater Houston Retina Research","startDate":"2012-04","conditions":"Proliferative Diabetic Retinopathy","enrollment":""},{"nctId":"NCT01189461","phase":"PHASE3","title":"Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01","conditions":"Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy","enrollment":46},{"nctId":"NCT01100307","phase":"PHASE3","title":"A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05","conditions":"Macular Edema, Diabetic Mellitus, Retinal Disease","enrollment":243},{"nctId":"NCT01486238","phase":"PHASE4","title":"Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study","status":"COMPLETED","sponsor":"Valley Retina Institute","startDate":"2009-04","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT00460408","phase":"","title":"Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":"Macular Degeneration","enrollment":501},{"nctId":"NCT00446381","phase":"NA","title":"Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-10","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":28},{"nctId":"NCT00858208","phase":"","title":"Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":86},{"nctId":"NCT01487044","phase":"","title":"A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema","status":"AVAILABLE","sponsor":"Retina Institute of Hawaii","startDate":"","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01487070","phase":"PHASE1","title":"A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Retina Institute of Hawaii","startDate":"2011-04","conditions":"PDR","enrollment":5},{"nctId":"NCT01486771","phase":"PHASE4","title":"Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)","status":"UNKNOWN","sponsor":"Valley Retina Institute","startDate":"2007-11","conditions":"Proliferative Diabetic Retinopathy","enrollment":30},{"nctId":"NCT00788177","phase":"PHASE3","title":"Subretinal Macugen® for Neovascular Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"Klinikum Ludwigshafen","startDate":"2008-11","conditions":"Age-related Macular Degeneration","enrollment":10},{"nctId":"NCT01245387","phase":"","title":"Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":"Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration","enrollment":1001},{"nctId":"NCT00324116","phase":"PHASE4","title":"Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Macular Degeneration","enrollment":81},{"nctId":"NCT00531336","phase":"PHASE2","title":"MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen","status":"COMPLETED","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2006-07","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT00295828","phase":"PHASE1","title":"A Pilot Study for the Treatment of Iris Neovascularization With Macugen","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2006-01","conditions":"Iris Neovascularization, Diabetic Retinopathy","enrollment":10},{"nctId":"NCT00358423","phase":"PHASE1, PHASE2","title":"The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-07","conditions":"Cystoid Macular Edema","enrollment":1},{"nctId":"NCT00346983","phase":"PHASE1, PHASE2","title":"Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-06","conditions":"Cystoid Macular Edema","enrollment":4},{"nctId":"NCT00088283","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-05","conditions":"Retinal Vein Occlusion","enrollment":90},{"nctId":"NCT00312351","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-04","conditions":"Macular Degeneration","enrollment":262},{"nctId":"NCT00354445","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD","status":"UNKNOWN","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-06","conditions":"Age-Related Macular Degeneration (AMD)","enrollment":1000},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":"Age-Related Macular Degeneration","enrollment":360},{"nctId":"NCT00321997","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2001-05","conditions":"Age-Related Macular Degeneration","enrollment":540},{"nctId":"NCT00087763","phase":"PHASE2","title":"Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-03","conditions":"Macular Degeneration","enrollment":135},{"nctId":"NCT00215670","phase":"PHASE2, PHASE3","title":"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-11","conditions":"Age-Related Macular Degeneration","enrollment":125},{"nctId":"NCT00040313","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-10","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00088192","phase":"NA","title":"Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-07","conditions":"Macular Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AORTIC ARTERIOSCLEROSIS"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HIP FRACTURE"},{"count":1,"reaction":"LUMBAR SPINAL STENOSIS"},{"count":1,"reaction":"NEPHROLITHIASIS"},{"count":1,"reaction":"VITRECTOMY"},{"count":1,"reaction":"VITREOUS HAEMORRHAGE"}],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Macugen"],"phase":"marketed","status":"active","brandName":"pegaptanib sodium injection","genericName":"pegaptanib sodium injection","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}